Hormones
Also known as: Decreased, Diminished, Inadequate, Under
Methodology & AI Transparency ⓘ
Hormones Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hormones are your body's chemical messengers.
- 2 Real-world patient consensus: Diagnostic registry E29.1: Hormones is managed within Men's Health & TRT (aka Decreased).
- 3 Typical cash cost range: Workup highlights for Hormones (E29.1): blood pressure) [Hormones E29.1].
- 4 Top reported side effects / signs: Longitudinal Hormones monitoring tracks LH, FSH & in Hormones (E29.1: SHBG) toward LH/FSH 2.5 – 8.0 mIU/mL (E29.1).
Ask our AI Specialists anything about Hormones
What Is Hormones?
Hormones are your body's chemical messengers. They travel in your bloodstream to tissues or organs. They work slowly, over time, and affect many different processes, including: Growth and development Metabolism - how your body gets energy from the foods you eat Sexual function Reproduction Mood Endocrine glands, which are special groups of cells, make hormones. The major endocrine glands are the pituitary, pineal, thymus, thyroid, adrenal glands, and pancreas. In addition, men produce hormones in their testes and women produce them in their ovaries. Hormones are powerful. It takes only a tiny amount to cause big changes in cells or even your whole body.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Hormones (E29.1) center on impaired cavernosal endothelial in Hormones (E29.1: nitric oxide-cGMP smooth-muscle). Cross-referenced with NIH MeSH (Hormones), targeted men's health & trt interventions aim to normalize LH, FSH & in Hormones (E29.1: SHBG).
Common Symptoms & Clinical Signs
- • Growth and development
- • Metabolism - how your body gets energy from the foods you eat
- • Presentation of Hormones (E29.1): reduced sexual desire, in Hormones (E29.1: fewer spontaneous morning)
- • Secondary Hormones clinical sign: loss of lean in Hormones (E29.1: muscle recovery, rising)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hormones Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E29.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: LH, FSH & in Hormones (E29.1: SHBG) | LH/FSH 2.5 – 8.0 mIU/mL (E29.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hematocrit & Total in Hormones (E29.1: PSA) | Hct < 50%; age-appropriate PSA (E29.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Hormones (E29.1: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (E29.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hormones
Treatment selection for Hormones depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hormones)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone supplementation and bone: What a 3,103-Participant Study Found TRT is able to inhibit bone resorption and increase bone mass, particularly at the lumbar spine level and when the duration is long enough to allow the anabolic effect of T and estrogens on bone metabolism to take place. Journal of endocrinological investigation • 2022-05-15 • Meta-Analysis | N = 3,103 | 99/100 | PMID 35041193 ↗ |
| New Insights on Prostate Safety Events During Testosterone Replacement Therapy in Men With: What a 5,246-Participant Study Found A total of 5204 men (mean [SD] age, 63.3 [7.9] years) were analyzed. JAMA network open • 2023-12-01 • Randomized Controlled Trial | N = 5,246 | 96/100 | PMID 38150256 ↗ |
| Can This Approach Help? Inside the Latest Research on [Perspectives] Derek Griffith: transformative leader in men's We don’t know a lot about men's health”, says Derek Griffith, who is one of the authors of a new Lancet Series on men's health. The Lancet • 2026-10-31 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 96/100 | PMID LANCET-593963419 ↗ |
| New Insights on Effect of metformin therapy on serum thyrotropin and free thyroxine: What a 1,147-Participant Study Found Metformin reduces TSH levels in hypothyroid patients; however, it has no effect on TSH levels in euthyroid patients. Scientific reports • 2023-10-31 • Meta-Analysis | N = 1,147 | 94/100 | PMID 37907510 ↗ |
| New Insights on Impact of subclinical hypothyroidism on core reproductive hormones and ovarian: What a 3,114-Participant Study Found Current evidence shows no significant differences in FSH, LH, estradiol, or total testosterone levels between SCH and euthyroid PCOS controls, while the evidence for prolactin. Frontiers in endocrinology • 2026-01-15 • Meta-Analysis | N = 3,114 | 94/100 | PMID 42798498 ↗ |
Hormones Patient Community & “People Like Me” Threads
Filter Hormones community threads and patient logs by age, biological sex, dosage, and treatment duration.